SINGAPORE, August 18 — AIGP Health, a clinician-founded AI health tech company based in Singapore, has officially received Class A regulatory approval from the Health Sciences Authority (HSA) for its proprietary AI-powered clinical assistant, making it the first company in Singapore to secure this designation for such a tool.
This milestone enables AIGP to commence distribution of its solution to clinics and telehealth providers nationwide, and beyond.
The platform, built by a team of practising doctors, leverages natural language processing to support health care professionals with real-time note-taking, patient data summarisation, and consultation prompts. Crucially, the system is not autonomous, all medical decisions remain under physician control, which aligns with HSA’s guidelines for low-risk medical software (Class A).
The approval affirms AIGP Health’s commitment to building tools that augment, rather than replace, human clinical judgement, a stance increasingly advocated by Singapore’s regulators as part of a broader framework for responsible AI in medicine.
“Regulatory approval isn’t just a milestone for us, it’s an affirmation of our belief that technology can support, not substitute, the human touch in health care,” said Dr Anindita Santosa, co-founder and CEO of AIGP Health.
“This approval allows us to move from pilots to deployment, and bring our platform to more clinics, GPs, and telehealth providers, easing the administrative burden for doctors and improving continuity of care for patients.”
AIGP’s solution has already been deployed in pilots across Singapore and Australia, where general practitioners use the AI assistant to streamline documentation, prompt relevant clinical questions during consults, and surface red flags in patient history.
The company is also working with Borderless Healthcare Group to expand into Indonesia and Malaysia, marking its regional growth trajectory.
With the Class A certification now secured, AIGP Health has begun commercial conversations with more health care providers, particularly telehealth platforms, which stand to benefit from the platform’s ability to pre-fill documentation, flag missing information, and improve consult quality in fast-paced digital settings.
In addition to regulatory approval, AIGP Health is now SOC 2 compliant, reflecting its adherence to industry best practices in data privacy, security, and operational integrity, a critical trust marker as it scales into new markets and systems.
The company’s security framework is built on industry standards and tailored for AI‑powered health care, with policies and controls designed to safeguard sensitive clinical data while enabling innovation.
This development is particularly timely, as Singapore continues to enhance its regulatory frameworks for digital health. In March 2025, HSA opened public consultation on a regulatory sandbox for AI-based Software as a Medical Device (AI-SaMD), proposing exemptions and new risk classifications for assistive AI tools.
AIGP’s approval positions it as a trailblazer in this evolving regulatory environment, demonstrating what responsible AI deployment in health care looks like.
“This milestone gives us the regulatory trust and momentum to move forward on several fronts — including the development of more modular, specialty-specific features, such as rheumatology and chronic care,” added Dr Santosa.
“It also opens doors to integrate our system more deeply into electronic health records (EHRs), and eventually into diagnostic workflows — all while ensuring that doctors stay in charge.”
As part of its product roadmap, AIGP is building its own integrated EHR system to better support voice commands, clinical ordering, and data integration, a move designed to make workflows more intuitive and less fragmented. The team is also exploring future capabilities such as image-based circulatory assessment and multimodal diagnostics.
Known as “Anzu”, AIGP’s flagship agentic AI platform orchestrates the full patient journey across intake, triage, documentation, and follow‑up, with multilingual support (English, Bahasa Melayu, Chinese, Tamil, and Bahasa Indonesia), real‑time evidence‑based reasoning, and seamless integration into existing clinic tools.
The regulatory approval also signals growing maturity for the startup, which previously operated on pre-seed and seed-stage capital. AIGP Health is now preparing for its seed fundraising round in Q1 2026, with both HSA and SOC 2 credentials expected to strengthen its position among investors.
“Our long-term mission is to help doctors spend more time listening to their patients and less time typing,” said Dr Santosa. “This approval brings us one step closer to that future, where AI lightens the load, and health care becomes more human again.”
